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In diabetes, one of the most important causes of morbidity and mortality is vasculopathy. Though flaxseed (FXS) is 
known for improving cardiovascular health, only limited studies are available on FXS concerning diabetic vascular 
reactivity. Hence, in this study, we studied vascular reactivity changes after FXS treatment on streptozotocin (STZ)-induced 
diabetic rat aortae. Female Wistar rats were divided into following four groups: control (C), FXS treated (CT), diabetic (D), 
and FXS treated diabetic (DT) groups. FXS (0,714 g/kg/day; orally) was started after one week of STZ injection and was 
given for 12 weeks, phenylephrine (Phe)-induced contractions were obtained on isolated aortic rings in the presence of 
indomethacin, L-NAME and superoxide dismutase (SOD), individually. Phe-responses were increased significantly in  
D group and completely improved after FXS intake, whereas FXS increased vascular reactivity to Phe in C group. 
Indomethacin incubation significantly attenuated Phe-induced contractions in all groups of aorta, particularly in D group.  
L-NAME incubation significantly increased Phe responses in all groups except D group. SOD incubation decreased the 
contractions efficiently in D group. The decreament was much lower in DT compared to D group, but reverse effects were 
observed in CT group. Our findings suggest FXS may provide beneficial effects on diabetes-induced vascular reactivity 
changes through NO and prostaglandin dependent pathways, but in healty condition FXS may have adverse effect probably 
via pro-oxidant activity. 
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Diabetes mellitus (DM) is associated with an 
increased risk of cardiovascular disease such as 
coronary heart disease, peripheral arterial disease and 
hypertension. Oxidative stress (OS) is a feature of 
DM and vascular endothelium is a major target of OS 
playing a critical role in the pathophysiology of 
vascular diseases, and its alteration significantly 
contributes to diabetic vascular pathology. 
Endothelial dysfunction is characterized by a 
reduction of vasodilators and/or an increase in 
endothelium-derived contracting factors (EDCFs) in 
DM. Although there are different mechanisms that 
induce the process of endothelial dysfunction in DM, 
hyperglycemia is the main mediator. Observations 
suggest that the damage from hyperglycemia on 




Flaxseed (FXS), Linum usitatissimum (Linn.) 
(Linaceae) (flax), also known as linseed, have various 
active compounds which make FXS an important 
plant in traditional medicine. It has various 
beneficial effects in dyslipidemia, cardiovascular 
diseases and diabetes
5-9
. From a nutritional 
perspective, flax is a well-known plant because of its 
oil, protein, fiber, lignan content and others.
 
FXS is 
rich in α-linolenic acid (ALA) and secoiso-
lariciresinol diglucoside (SDG) that have cardio-
protective and anti-atherogenic properties
5,10-12
. The 
available data sustain that the cardioprotective 
properties of FXS, are due not only to hypo-
cholesterolemic effects but also to several ways like 
antioxidative, anti-inflammatory and antithrombotic 
effects, and previous studies reported that FXS 
intake improve glycemic control in diabetes
6,7,13-15
. 
We have already shown that 12-week FXS 
supplementation has beneficial effects in 
glucotoxicity via pentose phosphate pathway and 
glutathione-dependent enzyme activities in several 
tissues of streptozotocin (STZ)-diabetic rats
16
. Here, 
we studied the vascular reactivity results in aortae 
obtained from the same animals.  
—————— 
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Material and Methods 
 
Animals, diabetes induction and treatment 
Female Wistar rats (n=32) weighing 180-210 g 
were used. They were housed under standard 
laboratory conditions (21±2ºC, 12-h light/dark cycle) 
during experimental period. Standard pellet diet and 
water were supplied ad libitum. The experiments were 
approved by the Animal Care Ethics Committee of 
Ankara University. The principles of laboratory 
animal care (NIH publication No.85-23, revised 1985) 
were observed. 
 
After 12 h starvation, diabetes was induced by i.p. 
injection of 40 mg/kg of STZ, freshly dissolved in 
cold citrate buffer, pH 4.5. Only citrate buffer was 
given to control rats. After one week following STZ 
application, blood was obtained from tail vein and 
glucose levels were measured using a hand-held 
glucometer (Roche Diagnostisc, Mannheim, 
Germany). Rats with glucose levels higher than  
250 mg/dL were considered as diabetic
16
. They were 
randomly divided into four groups: Gr. I, Control  
(C; n=7; animals were given orally only 
vehicle:carboxymethyl cellulose (CMC: 0.01%) in 
distilled water for 12 weeks ); Gr. II, Control treated 
(CT; n=9; animals treated orally with FXS 0,714 g/kg/day 
in vehicle for 12 weeks); Gr. III, Diabetic (D; n=7; 
animals were given orally only vehicle for 12 weeks); 
and Gr. IV, Diabetic treated (DT; n=9; animals treated 
orally with FXS in vehicle for 12 weeks). A flow 
diagram can be seen in Fig. 1. 
 
Commercial FXS provided locally (Damiana 
Natural Products, Istanbul, Turkey, contained 20% 
omega-3 fatty acid) and they were crushed with a 
mixer, suspended with CMC in distilled water and 
immediately administered by an oral gavage at a 
dosage of 0,714 g/kg/day. This dose was choosen 
according to the previous clinical studies (50 g/adult 
(70 kg)/day)
17
. The same amount of CMC solution 
were given to the control group for the same period. 
After 12-week treatment the rats were anesthetized, 
blood samples were collected from heart, the plasma 
were stored at 80° C. Thoracic aortae were 
attentively cleaned from connective tissue and cut into 
pieces approximately 4 mm in length for vascular 
reactivity studies. 
 
Vascular reactivity studies  
The aortic rings were hanged on a organ bath at 37°C 
containing 20 mL Krebs’ solution (in mM: NaCl 118, 
KCl 4.7, NaH2PO4 1.2, NaHCO325, MgSO4.7H20 1.2, 
glucose 11.2, CaCl2 2.5) aerated with 95 % O2, 5 % 
CO2 mixture (pH 7.4). The rings were streched to an 
optimal resting tension of 2 g and were equilibrated 
for 60 min
18
. The isometric tension was recorded 
using a force displacement transducer connected to an 
acquisition system (Commat Ltd., Ankara, Turkey). 
At the end of the equilibration time, aortic rings were 
exposed twice to 60 mM KCl to check the rings’ 
functions. Subsequently, the endothelial integrity was 
examined using acetylcholine (Ach: 10 mM) on rings 
pre-contracted with phenylephrine (Phe; 10
-6
 M). 
After washout time (30 min) cumulative 





were obtained in all group of rings. After the 
experiment the tissues were allowed to recuperate for 
30 min and the solution was replaced every 15 min 
before any protocol was started. To determine the 
vasoconstrictor effect of cyclooxygenase (COX) 
pathway, the rings were incubated with 10
-5
 M 
indomethacin (INDO: an inhibitor of cyclooxygenase 
derived prostanoids synthesis) 20 min before 
cumulative Phe applications. The other protocols were 
done with incubating L-nitro arginine methyl ester  
(L-NAME; a non selective nitric oxide synthase, 10
-5
 M) 
to examine the role of NO (nitric oxide) released from 
endothelial cells on Phe contractility, and superoxide 
dismutase (SOD; 1500U; inactivates superoxide radicals 
and increases bioavailability of NO) for 20 min before 
cumulative Phe applications. Endothelium-independent 









All chemicals were analytical grade and purchased 




Statistical analysis was carried out by one-way 
ANOVA followed by post hoc Newman-Keuls test 




Fig. 1 — Schematic diagram of experimental groups and the 
treatments. [Groups: Control (C); control treated (CT); diabetic 
(D); and diabetic treated (DT)] 
 




Software, USA), *P <0.05, **P <0.01, ***P <0.001 
were considered significant.  
 
Results and Discussion 
Body weight, blood glucose and triglyceride levels 




Vascular reactivity results 
FXS treatment normalized the Phe contractile 
profile on aortae from D rats (the contractions in DT 
group were similar to C group). But Phe contractile 
profile was increased significantly in CT group 
compared to C (and DT) groups. There was no 
statistical difference between CT and D groups (Fig. 2). 
After incubation with INDO, contractile responses to 
Phe significantly decreased in all aortic groups 
especially in D and DT groups (Fig. 3). After 





concentrations of Phe, significant differences were 
observed compared with CT before incubation 
(p<0.001). In incubated C group there were 
significant decreases in contractility, but not as much 
as CT group. After incubation with SOD, although 
both of D and DT groups showed significant 
decreases to Phe constrictor responses, less constrictor 
effect was observed in D group (Fig. 4). Incubation of 
aortic rings with L-NAME, significantly increased the 
Phe vasoconstrictor responses in C, CT and DT 
groups, but in D group no significant change was 
observed (Fig. 5). No significant changes were 
observed in endothelium-independent relaxations 




 M) among the groups 
(n=5) (data not shown). 
In the present study, we have demonstrated that 
FXS has beneficial effects on impaired vascular 
reactivity in diabetic state, but not in healthy rats. It is 
known that diabetes triggers endothelial dysfunction, 
impaired vascular reactivity and atherosclerosis. In 
diabetic endothelial dysfunction, decrement in 
endothelium-dependent relaxing factors (EDRFs) and 
increment in EDCFs lead to vascular tone 
enhancement, platelet aggregation, and thrombus. OS 
increases in diabetic state in consequence of reactive 
oxygen species’ (ROS) overproduction together with 
decrease in antioxidative systems leading endothelial 
dysfunction. ROS causes reduction on nitric oxide 
(NO) bioavailability, and increases the effect of 
EDCFs. As a consequence, the endothelial balance is 






Fig. 2 — The cumulative concentration-response curve of 
phenylephrine (Phe) on aortic rings. [Values are mean ± SEM. 
Control (C) group (n=7), control treated (CT) group (n=9 each), 
diabetic (D) group (n=7), diabetic treated (DT) group (n=9). *P 





Fig. 3 — The cumulative concentration-response curves of 
phenylephrine (Phe) alone and in presence of indomethacin 
(INDO) on aortic rings. [Values are mean ± SEM. Control (C) 
group (n=7), control treated (CT) group (n=9). C INDO group’s 
statistical differences were shown as *P <0.05, **P <0.01,***P 
<0.001 vs. C group; CT INDO group’s statistical differences were 
shown as #P <0.05, ##P <0.01 vs. CT group. Diabetic (D) group 
(n=7), diabetic treated (DT) group (n=9). Statistical differences of 
D INDO group vs. D group were shown as ***P<0.001 and DT 
INDO group vs. DT group were shown as ##P <0.01, ###P <0.001] 
 




Diabetic (D) rat aortae showed increased vasoconstrictor 
responses to Phe relative to controls (C), in agreement 
with previous studies
18,20
. FXS treatment improved 
this defective responsiveness. It is known that EDCFs 
involve activation of cyclooxygenases (COXs) and 
release certain prostanoids that stimulate thromboxane 
(TX) prostanoid receptors (TPRs). The stimulation of 
TPRs elicits vascular contraction, vascular smooth 
muscle cell proliferation, platelet aggregation and 
inflammation. Additionally, the generation of 
endothelial vasodilator-antiaggregant prostacyclin 
(PGI2) via COX-1 decreases, and generation of 
vasoconstrictor-aggregant  TXA2  in  endothelium and 
in platelets increases in diabetic state. This imbalance  
of the PGI2/ TXA2 ratio partially account for 
atherogenesis in diabetes,
 
and COX-1 and COX-2 
produce vasoconstrictor prostanoids in diabetic 
aorta
3,22,23
. Thus, first, the effect of prostanoids’ role 
on increment in Phe responses with FXS treatment in 
our diabetic aortae is investigated. After incubation 
with non-selective COX inhibitor indomethacin 
(INDO), all of the aortic groups showed significant 
decrease to Phe constrictor responses, especially D 
group. Although significant decrease occured in DT 
group, maximum decrease was observed in D group. 
Further, when compared to CT group, a significant 
decrease was observed in CT INDO group and also 




Fig. 4 — The cumulative concentration-response curve of 
phenylephrine (Phe) alone and in presence of superoxide 
dismutase (SOD) on aortic rings. [Values are mean ± SEM. 
Control (C) group (n=7), control treated (CT) group (n=9 ). 
Statistical differences of C SOD group were shown as *P <0.05, 
**P <0.01, ***P <0.001 vs. C group; CT SOD group were shown 
as #P<0.05, ##P <0.01, ###P <0.001 vs. CT group. Diabetic (D) 
group (n=7), diabetic treated (DT) group (n=9). Statistical 
differences of D SOD group vs. D group were shown as *P <0.05, 
**P <0.01, ***P <0.001; DT SOD group vs. DT group were 





Fig. 5 — The cumulative concentration-response curve of 
phenylephrine (Phe) alone and in presence of L-NAME on aortic 
rings. [Values are mean ± SEM. Control (C) group (n=7), control 
treated (CT) group (n=9). Statistical differences of C L-NAME 
group were shown as *P <0.05, **P <0.01, ***P <0.001 vs.  
C group; CT L-NAME group were shown as #P <0.05,##P <0.01 
vs. CT group. Diabetic (D) group (n=7), diabetic treated (DT) 
group (n=9). DT L-NAME group vs. DT group were shown as  
##P <0.01] 
 




in C INDO group significantly. These results suggest 
that much more vasoconstrictor COX products are 
generated in D group aorta and FXS intake reduced 
these COX products in D group.  
 
It has been reported that α-linolenic acid (ALA) 
decreases TXA2 and increases PGI2 in vessels
3,24
. This 
may enhance endothelium-dependent vasodilation. 
Additionally, the inhibitory effect of FXS oil on 
platelet aggregation is indicated in rabbits
25
. Thus, TX 
plays a role on vascular dysfunction in diabetic state. 
Notably, in the present study, inhibition of the COX 
pathway with INDO decreased aortic contraction to 
Phe in D group much more than C group. ROS 
production has a major role in the development of 
vascular dysfunction in diabetes increasing the 
vasoconstrictor eicosanoids’ generation and tends to 
show more inflammatory, vasoconstrictor, pro-
thrombotic effect
3,19
. A decrement was reported in 
EDRFs responses associated with enhancement in 
COX-1, COX-2 expression, TXA2, PGE2 and OS in 
type 2 diabetic rat mesenteric arteries
26
. It was 
concluded that endothelial dysfunction in diabetes can 
be reversed in part by treatment with eicosapentaenoic 
acid (omega-3 fatty acid), TXA2 synthase inhibitor 
and antioxidant
3
. Upregulation of protein kinase C 
(PKC) mediated COX-2 is related with the increment 
of TXA2 and decrement of PGI2 release in diabetes
4
. 
Hyperglycemia increases PKC activity and this 
upregulates peroxidase enzymes and COX pathway, 
with resultant excessive generation of ROS/nitrogen 
species. This process was amplified when the 
antioxidative systems become compromising. All 
these cellular mechanisms provide support for the usage 




FXS lignan has antioxidant properties as a 





) and hydrogen peroxide 
(H2O2)
27-29
. In the present study, Phe contractions 
were reduced more in the presence of SOD in  
D group aortae than that of DT group. Also, more 
reduction was observed in aortae from CT group than 
C group aortae after SOD incubation. On the other 
hand, Nunes et al.
30
 stated that 15 days of FXS oil 
treatment in healthy rats adversely increases aortic 
vascular reactivity to Phe by increasing COX-2 
mediated TXA2 and ROS generation. It is mentioned 
that ALA can easily be oxidized, and FXS oil can also 
cause peroxidation of lipids which may adversely 
affect the vessels, and linoleic acid (LA) can increase 
PG2s and TX, which augments vascular tonus. These 
results could explain why Phe contractions were 
increased in CT group in our study and SOD 
incubation was more effective in aortae from CT 
group than that of C group. It is known that an agent 
can be both pro- or anti-oxidant according to 
physiological state. FXS contains fatty acids, such as 
polyunsaturated fatty acids including ALA and LA, 
dietary fibers and phytoestrogen lignans, and because 
FXS posesses antioxidant potential
 
it can be thought 
that FXS exerts important antioxidant effects, but, this 
is also has not been the case in some clinical studies. 
For example, two clinical trials have reported that  
3 weeks of FXS (50 g/day) or 4 weeks of FXS oil  
(20 g/day) treatment caused an increase on OS 
markers in hyperlipidemic adults, and LDL oxidation 
was observed in obese patients
31,32
. The effects of 
FXS on contractile and vasodilator responses are also 
contradictory in animal model experiments. For eg., 
for 6, 8 or 16 weeks of 10% FXS supplementation 
does not alter norepinephrine-induced vasoconstriction 
or Ach-induced relaxation responses in hyper-
cholesterolemic rabbits
33
. However, another study 
reported that 20% FXS diet increases endothelial 




EDRFs consist of nitric oxide (NO), prostacyclin, 
and endothelium-derived hyperpolarizing factor 
(EDHF). Impaired endothelium derived vasodilation 
and basal NO-dependent vasodilatory tone is 
represented in several diabetic animals and in diabetic 
patients
2,4
. Several mechanisms are exposed for 
impaired endothelial NO responses in diabetic vessels, 
consisting of damages in signal transduction or 
substrate availibility, damage in the release of NO, 
increment in NO breakdown and increment in EDCFs. 
To investigate the effect of FXS intake on NO 
modulation of Phe-contractile responses, the aortic 
rings were incubated with L-NAME, a nitric oxide 
synthase (NOS) inhibitor. In D group, no significant 
change was observed by incubation, however Phe 
contractions were enhanced in DT-incubated group. 
These results may indicate that FXS treatment has no 
effect on NO production, but may improve vascular 
reactivity changes in DT group by reducing 
superoxide anion (O2
-
) generation and thus increasing 
NO bioavailability. Rapid destruction of NO occurs in 
diabetic vessels because of extensive OS, and it is 
well known that the increment in ( O2
-
) is related with 
the accelerated break down of NO
2,4
. Thus, FXS may 
protect the vasculature by inhibiting the disruption of 
NO with antioxidant property in diabetes.  




As a common observation, we found that sodium 
nitroprusside (SNP)-induced relaxations in diabetic 
aortae (an endothelium-independent, cGMPmediated 
relaxant agent) were comparable to control aortae 
indicating FXS treatment did not affect vascular 
smooth muscle responsiveness.  
 
FXS consists of plant lignans, and seco-
isolariciresinol diglucoside (SDG) lignan in FX, and 
its metabolites possess potent antioxidant effect
35-37
. 
SDG has a scavenger activity on ROS. Moreover, it is 
reported that SDG has a role in delaying the 
development of diabetes in rat model of insulin 
resistance counteracting OS
37
. Further, synthetic SDG 
exerts anti-hyperglycemic effect in STZ- diabetic rats 
by protecting the liver from OS, and improves insulin 
sensitivity
38
. Hence, the improved endothelial 
vasodilation, as previously reported could be the 
effects of lignans in our diabetic animals. In type 2 
diabetic rat model, dietary FXS oil (does not contain 
lignan and fibre) and fish oil reduces protein glycation 
and inflammation in liver
39,40
. Further, a daily FXS 
supplementation for 12 weeks in pre-diabetic obese or 
overweight individuals decreases glucose and insulin 
levels and improves insulin sensitivity
6
. We have 
already reported that FXS intake reduces glucose and 
TG levels in our diabetic rats, and has beneficial 
effects in glucotoxicity via regulating pentose 
phosphate pathway and glutathione-dependent 
enzyme activities in several tissues
16
. Anti-
hyperglycemic effect of FXS extracts has also been 
shown in alloxan or STZ diabetic rats and mice or 
hamsters fed with a high-fat diet
41-44
. However, as 
mentioned above, there are adverse clinical results on 
FXS oil supplementation which increases OS markers 
in hyperlipidemic or insulin resistant subjects. Also, a 
study on partially defatted FXS supplementation of 
hyperlipidemic subjects has reported significantly 
reduced serum thiol groups of proteins, possibly 
indicating oxidative activity
45
. Thus, the effects of 
FXS on markers of OS need further study. An agent 
can be both pro- or anti-oxidant according to dosage 
or physiological /pathological state and / or organ 
species. For example, vitamin C which is an 





The results of this study indicate that FX 
supplementation to diabetic rats improves diabetes-
induced vascular reactivity changes to vaso-
constriction and endothelial dependent relaxation by 
increasing NO bioavailability and modulating PG 
dependent pathways. Thus, FXS may protect the 
vasculature with antioxidant property in diabetes but, 
in healthy state FXS supplementation may augment 
vascular reactivity to vasoconstrictors. To the best of 
our knowledge, this is the first study to identify the 
favourable effect of the FXS supplementation on 
vascular reactivity in STZ-diabetic rats. More 
research is needed to clarify the mechanism (s) for 
beneficial effects of FXS in diabetic vascular 
reactivity, and also possible vascular adverse effects 
in healthy state. Although the clinical significance of 
our results is not clear, healthy people should avoid 
uncontrolled use of FXS supplements. 
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